2. Signaling Pathways
  3. Cell Cycle/DNA Damage
  4. Polo-like Kinase (PLK)

Polo-like Kinase (PLK)

Polo-like Kinase (PLK)

Related Products

PDF 0.57 MB

Polo-like Kinases (PLKs) are a group of highly conserved serine/threonine protein kinases that play a key role in processes such as cell division and checkpoint regulation of mitosis. In mammals, five PLKs (PLK 1-5) encompass diverse roles in centrosome dynamics, spindle formation, intra S-phase and G2/M checkpoints, and DNA damage response.

PLKs are characterized by their Polo-box domain, which mediates protein interactions. They are additionally controlled by phosphorylation, proteolysis, and transcription, depending on the biological context. PLKs are now recognized to link cell division to developmental processes and to function in differentiated cells.

Polo-like Kinase (PLK) Isoform Specific Products:

Polo-like Kinase (PLK) Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-172943
    PLK1/PRC1-IN-1
    		Inhibitor
    PLK1/PRC1-IN-1 (compound B4) is a PLK1/PRC1 protein complex formation inhibitor. PLK1/PRC1-IN-1 can be used in the study of non-small cell lung cancer (NSCLC) .
    PLK1/PRC1-IN-1
  • HY-179149
    PLK4-IN-6
    		Inhibitor
    PLK4-IN-6 (compound C05) is an PLK4 inhibitor (IC50 < 0.1 nM). PLK4-IN-6 has anti proliferative activity against various tumor cells, such as IMR-32 (IC50 = 0.948 μM), MCF-7 (IC50 = 0.979 μM), H460 (IC50 = 1.679 μM) cells. PLK4-IN-6 can significantly induce cell apoptosis and block the cell cycle. PLK4-IN-6 can be used for research on various types of cancer.
    PLK4-IN-6
  • HY-RS10718
    Plk3 Mouse Pre-designed siRNA Set A
    		Inhibitor

    Plk3 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Plk3 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
    Plk3 Mouse Pre-designed siRNA Set A
  • HY-RS10713
    Plk1 Rat Pre-designed siRNA Set A
    		Inhibitor

    Plk1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Plk1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
    Plk1 Rat Pre-designed siRNA Set A
  • HY-173233
    PLK1-IN-14
    		Inhibitor
    PLK1-IN-14 (Compound Hit-4) is a selective PLK1 inhibitor. It has an IC50 of 22.61 pM against PLK1 and an IC50 of 0.09 nM for inhibiting the proliferation of DU - 145 prostate cancer cells. PLK1-IN-14 can be used in the research of prostate cancer.
    PLK1-IN-14
  • HY-RS10722
    Plk4 Rat Pre-designed siRNA Set A
    		Inhibitor

    Plk4 Rat Pre-designed siRNA Set A contains three designed siRNAs for Plk4 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
    Plk4 Rat Pre-designed siRNA Set A
  • HY-180111
    PLK4-IN-7
    		Inhibitor
    PLK4-IN-7 is a selective and orally active PLK4 inhibitor with an IC50 value of 7.9 nM. PLK4-IN-7 exhibits potent antitumor activity and favorable metabolic stability. PLK4-IN-7 can be used for the research of tumors such as neuroblastoma.
    PLK4-IN-7
  • HY-111090
    GSK461364 analogue 1
    		Inhibitor
    GSK461364 analogue 1 is a thiophene-based PLK1 inhibitor with a PLK1 IC50 of 2 nM and a PLK3 IC50 of 630 nM. GSK461364 analogue 1 also acts as an inhibitor of Nek2 kinase (IC50: 21 nM). GSK461364 analogue 1 has a solubility of ≥190 μM in pH 7.4 PBS and a human plasma protein binding rate of 91.5%. GSK461364 analogue 1 can be used in studies related to colon cancer, lung cancer, breast cancer and ovarian cancer.
    GSK461364 analogue 1
  • HY-164955
    TTK/PLK1-IN-1
    		Inhibitor
    TTK/PLK1-IN-1 (Formula I) is the inhibitor for threonine tyrosine kinase (TTK) and polo-like kinase 1 (PLK1) with IC50 of 7 nM and 72 nM. TTK/PLK1-IN-1 regulates spindle assembly checkpoint (SAC), and exhibits antitumor efficacy against TNBC.
    TTK/PLK1-IN-1
  • HY-120279A
    CFI-400437
    		Inhibitor
    CFI-400437 is an indolinone-derived, ATP-competitive kinase inhibitor with high selectivity for PLK4 (IC50 of 0.6 nM).
    CFI-400437
  • HY-115589
    YLT-11
    		Inhibitor
    YLT-11 is a potent, selective and orally active PLK4 inhibitor with Kd values of >10000, 653, >10000, 5.2 nM for PLK1, PLK2, PLK3, PLK4, respectively. YLT-11 shows antiproliferative activity. YLT-11 induces Apoptosis and cell cycle arrest at G2/M phase. YLT-11 show anticancer activity.
    YLT-11
  • HY-134775A
    PLK4-IN-3
    		Inhibitor
    PLK4-IN-3 is a less active absolute stereochemistry of PLK4-IN-1. PLK4-IN-1 is a PLK4 inhibitor, with an IC50 of 0.65 μM.
    PLK4-IN-3
  • HY-148974
    PLK1-IN-5
    		Inhibitor
    PLK1-IN-5 is a potent PLK1 inhibitor with an IC50 of < 500 nM. PLK1-IN-5 shows anticancer effects (WO2008113711A1; compound I-4).
    PLK1-IN-5
  • HY-146792
    PLK1-IN-4
    		Inhibitor
    PLK1-IN-4 is a potent and selective PLK1 inhibitor with IC50 < 0.508 nM. PLK1-IN-4 has broad antiproliferative activity against a variety of cancer cell lines. PLK1-IN-4 induces mitotic arrest at the G2/M phase checkpoint, leading to cancer cell apoptosis. PLK1-IN-4 can be used for researching hepatocellular carcinoma.
    PLK1-IN-4
  • HY-139652
    PLK1-IN-2
    		Inhibitor
    PLK1-IN-2 is a PLK1 kinase inhibitor with an IC50 value of 0.384 μM.
    PLK1-IN-2
  • HY-172364
    PLK1-IN-12
    		Inhibitor
    PLK1-IN-12 is a highly selective and orally active PLK1 inhibitor with an IC50 of 20 nM. PLK1-IN-12 shows more selective for PLK1 than PLK2 (IC50: >10000 nM) and PLK3 (IC50: 3953 nM). PLK1-IN-12 exhibits anticancer potency across a broad spectrum of cell lines. PLK1-IN-12 can be used in anti-leukemia research.
    PLK1-IN-12
  • HY-RS10714
    PLK2 Human Pre-designed siRNA Set A
    		Inhibitor

    PLK2 Human Pre-designed siRNA Set A contains three designed siRNAs for PLK2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
    PLK2 Human Pre-designed siRNA Set A
  • HY-181001
    POI ligand-4
    		Degrader
    POI ligand-4 is a PLK1 ligand and can be used for the synthesis of PROTACs, such as PROTAC PLK1 Degrader-3 (HY-181000).
    POI ligand-4
  • HY-RS10716
    Plk2 Rat Pre-designed siRNA Set A
    		Inhibitor

    Plk2 Rat Pre-designed siRNA Set A contains three designed siRNAs for Plk2 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
    Plk2 Rat Pre-designed siRNA Set A
  • HY-181769
    Anticancer agent 306
    		Inhibitor
    Anticancer agent 306 is a spiro tetramic acid derivative and a inhibitor of MMP1, MMP7 and PLK1. Anticancer agent 306 exerts antiproliferative activity against H1299, RKO and MCF-7 cells with IC50 values of 19.25 μM, 3.29 μM and 102.36 μM, respectively. Anticancer agent 306 can up-regulate p21 protein and down-regulate CCND1 and CCNB1 proteins to induce cell cycle arrest, regulate the expression of Bcl-2 and Bax to induce cell apoptosis. Anticancer agent 306 can down-regulate MMP1 and MMP7 proteins to inhibit tumor invasion and metastasis. Anticancer agent 306 can be used for the research of lung cancer, colorectal cancer, breast cancer.
    Anticancer agent 306
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity
Polo-like Kinase (PLK) Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.